Reply "XtalPi"Obtain 735-page prospectusNovember 30,XtalPi (QuantumPharm)XtalPi Holdings Limited (-P) officially submitted a Hong Kong IPO application under the new Rule 18C for specialized technology companies, with CITIC Securities acting as the sole sponsor.Referral. Key Focus Points of the Prospectus:New technologies such as artificial intelligence, quantum physics, and automation are transforming businesses and are considered to enhance production.Powerfully promote economic growth. XtalPi's partners in the drug research and development field include: Pfizer, Bayer, Merck, Johnson & Johnson/Janssen, Eli Lilly, Haisco, Hansoh, Hengrui, Shanghai Pharmaceuticals, and Huadong Medicine, among others. Additionally, an innovative ophthalmic drug company also submitted its prospectus for listing on the Hong Kong Stock Exchange on the same day.Cloudbreak Pharma, with a total financing of approximately 154 million US dollars, and the valuation of the last round of financing was 469 million US dollars. (Reply "Bokang Vision Cloud"Obtain a 646-page prospectus")
As of June 30, 2023, XtalPi has raised a total of $7.32 billion in financing. XtalPi's ability to attract such investment is related to its genetic makeup, with artificial intelligence, quantum physics, and automated laboratories being its main selling points.In traditional methods, 95% of experimental operations heavily rely on manual testing, leading to various drawbacks, such as labor...Increased operating costs, low production efficiency, risk of employee infection, etc.Automation is expected to become the key to industrial upgrading and reform.The major trend.
Founded in 2015, XtalPi has developed into a world-leading quantum physics-based artificial intelligence empoweredAn innovative R&D platform driven by robots, and improve speed, scale, novelty, and success rate inMade significant contributions to the field of drug design and discovery.We are also engaged in materials science (e.g., the design and discovery of bio-based materials,Application of New Compounds, New Chemical Surfactants and Catalysts in Agriculture, Cosmetics, and Healthcare ProductsSubstantial progress has been made in automation (such as automated chemical synthesis).Our goal is to completely transform the new type ofThe design and discovery of subsidiaries and materials, venturing into new fields under the guidance of our vision and strengths.
May 2021,XtalPiConsidered the possibility of conducting an initial public offering in the United States ("Proposed U.S. Listing"). During the process of the Proposed U.S. Listing, confidential application documents were submitted to the U.S. Securities and Exchange Commission for its review.XtalPiThe directors believe that they have provided satisfactory answers to the CSRC's questions and have conducted reviews, and there are no disagreements with the CSRC or other professionals regarding the proposed U.S. listing. In view of the listing regime set out in Chapter 18C of the Listing Rules,XtalPiThe board of directors decided to suspend the planned U.S. IPO and seek a listing in Hong Kong instead.
XtalPi's valuation from 2015Pre-A Round 10.3 Million YuanRMB After Multiple Rounds of Financing in July 2021Reaching $1.968 billion after Series D financing(Approximately 14 billion yuan RMB,Increased 1400 times in 7 years). Major investors include Tencent Investment (13.66%), Sequoia China (8.25%), Five Source Capital (7.94%), China Life Chengda (7.32%), PICC Health and Pension Fund (3.72%). Other investors include Aqua Elite Capital, Artisan Partners, Bopu Capital, Zhongding, Huaxing Capital, CICC Capital, CITIC Securities, CITIC Venture Capital, CMB International, Keda Investment, Duckling Fund, Epiphron Capital, FountainVest Partners, Red Fire Capital, FreeS Fund, Google, Mirae Asset, Orbimed, Cloud Nine Capital, SoftBank Vision Fund, China Biologic Products, Haosong Capital, and many more (71 shareholders in total)… The total number of shares is 3,219,399,761.
The combined shareholding percentages of co-founders Dr. Wen, Dr. Ma, and Dr. Lai, along with their respective family trusts, are 16.16%, 3.82%, and 2.73%, totaling 22.71%.With three wet lab experimental centers, and more than 200 robotic workstations and robots.XtalPi's revenue in the past few years: Over 35 million yuan in 2020, 62.79 million yuan in 2021, 133 million yuan in 2022, and nearly 80 million yuan in H1 2023.Net Loss:RMB 2.137 billion in 2021, RMB 1.438 billion in 2022, and RMB 620 million in the first half of 2023.
XtalPi Holdings Limited had approximately 1 billion yuan in cash and equivalents as of the end of the first half of 2023.
Follow the official account below to explore the world with you!
